Revance Therapeutics (NASDAQ:RVNC) has been given a $50.00 target price by stock analysts at Cantor Fitzgerald in a research report issued on Thursday, November 16th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 43.88% from the stock’s current price.
Several other equities analysts also recently commented on the stock. Mizuho assumed coverage on shares of Revance Therapeutics in a report on Thursday, November 16th. They set a “buy” rating and a $37.00 price target on the stock. Piper Jaffray Companies reiterated a “buy” rating and set a $28.00 price target on shares of Revance Therapeutics in a report on Friday, October 27th. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, JMP Securities assumed coverage on shares of Revance Therapeutics in a research report on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Revance Therapeutics has a consensus rating of “Buy” and an average target price of $38.14.
Revance Therapeutics (RVNC) traded up $8.75 during trading on Thursday, hitting $34.75. 8,133,983 shares of the stock were exchanged, compared to its average volume of 218,294. Revance Therapeutics has a 12-month low of $15.85 and a 12-month high of $37.20.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.06). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.64) earnings per share. research analysts anticipate that Revance Therapeutics will post -3.73 earnings per share for the current year.
In other news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total value of $179,208.00. Following the completion of the sale, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark J. Foley purchased 20,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average cost of $26.96 per share, with a total value of $539,200.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Over the last three months, insiders sold 44,026 shares of company stock valued at $1,135,234. 18.86% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Parametric Portfolio Associates LLC raised its stake in shares of Revance Therapeutics by 5.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 1,524 shares in the last quarter. American International Group Inc. raised its stake in shares of Revance Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 834 shares in the last quarter. FMR LLC raised its stake in shares of Revance Therapeutics by 216.9% during the 1st quarter. FMR LLC now owns 316,900 shares of the biopharmaceutical company’s stock worth $6,592,000 after acquiring an additional 216,900 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Revance Therapeutics by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock worth $18,056,000 after acquiring an additional 42,466 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Revance Therapeutics by 16.4% during the 1st quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock worth $3,711,000 after acquiring an additional 25,075 shares in the last quarter. 88.70% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Revance Therapeutics (NASDAQ:RVNC) PT Set at $50.00 by Cantor Fitzgerald” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/05/cantor-fitzgerald-reiterates-50-00-price-target-for-revance-therapeutics-inc-rvnc.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.